Change in Management
Berlin, Germany - April 30, 2024 ProBioGen AG (Berlin/Germany), a premier Contract Development and Manufacturing Organization (CDMO) and technology provider with extensive..
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Berlin, Germany - March 27, 2024 ProBioGen, a globally recognized and experienced Contract Development & Manufacturing Organization (CDMO), proudly announces a partnership with..
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Berlin, Germany - March 13th, 2024 ProBioGen, a leading CDMO of innovative solutions and services for biopharmaceutical development, is pleased to announce the execution of..
ProBioGen was Granted a New Patent for DirectedLuck® Transposase Technology
Berlin, Germany - December 14th, 2023 ProBioGen announced today that the Japan Patent Office (JPO) issued the first patent for the company’s DirectedLuck® technology. The powerful..
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
Berlin, Germany and Atlanta, Georgia - September 26, 2023 ProBioGen and GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against..
ProBioGen Launches Their Lentivirus Packaging Cell Line Lenti.RiGHT™
A Shortcut to Successful Lentivirus Manufacturing Boston, MA, USA and Berlin, Germany - May 17, 2023 ProBioGen today announced the launch of their lentivirus (LV) packaging cell..
Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX® Production Platform
Berlin, Germany – May 4, 2023 ProBioGen announces that their proprietary vaccine production cell line AGE1.CR.pIX® has been successfully used to manufacture a viral vector product..
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Mar 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
May 29, 2024
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Mar 27, 2024
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Mar 13, 2024
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
Sep 26, 2023
